UGT1A1 and cancer: Goetz M.P. et al. [42] aimed to define the MTD of the CAPIRINOX (capecitabine, irinotecan, and oxaliplatin) regimen depending on the UGT1A1 genotype in different cancer streams, but just considering the UGT1A1*28 variant, and concluding that the UGT1A1*28 genotype affects the tolerable dose and PK of the CAPIRINOX regimen.